Solute carrier family 12 member 1 (NKCC2) [1.3.1] (NKCC2 [1.3.1])

The Solute carrier family 12 member 1 (NKCC2) is a key membrane protein located in the apical membrane of the thick ascending limb (TAL) of the loop of Henle in the kidney [1.3.1, 1.3.2]. Its primary biological function is the electroneutral transport of one sodium, one potassium, and two chloride ions from the tubular lumen into the epithelial cells, accounting for approximately 20-25% of total renal salt reabsorption [1.2.1, 1.3.3]. This process is essential for maintaining electrolyte balance, regulating blood pressure, and establishing the medullary osmotic gradient required for urine concentration [1.3.1, 1.3.2]. Mutations in the SLC12A1 gene lead to Bartter syndrome type 1, a severe salt-wasting disorder characterized by hypokalemia, metabolic alkalosis, and hypercalciuria [1.3.1, 1.4.3]. NKCC2 is the primary pharmacological target for loop diuretics such as furosemide and bumetanide, which are used to treat hypertension and edematous conditions associated with heart failure, liver cirrhosis, and renal disease [1.1.3, 1.4.1]. However, inhibition of NKCC2 can lead to significant side effects, including electrolyte imbalances and ototoxicity, the latter resulting from the non-specific inhibition of the related NKCC1 isoform in the inner ear [1.3.2, 1.4.1].

Other names

SLC12A1 [1.3.1]BSC1 [1.3.1]BSC [1.3.5]CCC2 [1.3.5]Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1 [1.3.1]Na-K-2Cl cotransporter 2 [1.3.1]

Inhibition of the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, which disrupts the reabsorption of sodium, potassium, and chloride ions, thereby promoting diuresis and natriuresis [1.4.1, 1.4.3].